Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Qiu Li(Jiangsu University), Chunlei Jin(Jiangsu Hengrui Medicine (China)), Lizhu Lin(Guangzhou University of Chinese Medicine), Zishu Wang(Bengbu Medical College), Shukui Qin(81th Hospital of PLA), Hongming Pan(Sir Run Run Shaw Hospital), Shanzhi Gu(Central South University), Yuxian Bai(Harbin Medical University), Weijia Fang(Zhejiang Cancer Hospital), Xi Chen(National Taiwan University Hospital), Lei Chen(Shantou University), Lin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Aibing Xu(Nantong Tumor Hospital), Jun Li(First Affiliated Hospital of Guangzhou Medical University), Ping Yan(Jiangsu Hengrui Medicine (China)), Li Xu(Fujian Medical University), Cuncai Zhou(Jiangxi Provincial Cancer Hospital), Bangwei Cao(Capital Medical University), Zhenggang Ren(Ministry of Education of the People's Republic of China)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.4507
Cited by 36

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821